Medtronic Inc. (NYSE:MDT) is fielding a pair of lawsuits, one accusing it of product liability over its Sprint Fidelis implantable cardiac defibrillator leads and another alleging that it falsely marked some of its Endeavor stents with a pair of U.S. patents. The Minneapolis medical device monolith pulled the Sprint Fidelis leads from shelves worldwide in […]
It will be a new opportunity for the Endeavor stent system as it struggles with competition in the United States. One device analyst declared to Dow Jones News Service last month that Endeavor was an "also ran." Japan is the last major market for Endeavor in the $4 billion global stent market.
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.